Chart: FDA Has A Comments Craving: What The Agency Wants Stakeholders To Tell It About Its New Pregnancy Labeling Rule
You may also be interested in...
FDA's proposed regulation for the new format of the pregnancy section of labeling appears to offer firms a useful template for how to structure other risk disclosures about products
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials